Author

Dominik Kralj

PERFORMANCE OF INTESTINAL ULTRASOUND SCORES IN DETECTING ACTIVE CROHN'S DISEASE
PERFORMANCE OF INTESTINAL ULTRASOUND SCORES IN DETECTING ACTIVE CROHN'S DISEASE

Dominik Kralj  et al.

REAL-LIFE DATA OF TREATMENT PERSISTENCE IN PATIENTS WITH LONG-STANDING CROHN'S DISEASE TREATED WITH BIOLOGICS: RESULTS FROM A CROATIAN TERTIARY CENTER
REAL-LIFE DATA OF TREATMENT PERSISTENCE IN PATIENTS WITH LONG-STANDING CROHN'S DISEASE TREATED WITH BIOLOGICS: RESULTS FROM A CROATIAN TERTIARY CENTER

Dominik Kralj  et al.

IMPACT OF SARS-COV-2 PANDEMIC ON IBD PATIENTS IN OUR TERTIARY CENTRE - CROSS SECTIONAL STUDY
IMPACT OF SARS-COV-2 PANDEMIC ON IBD PATIENTS IN OUR TERTIARY CENTRE - CROSS SECTIONAL STUDY

Dominik Kralj  et al.

UTILITY OF VEDOLIZUMAB CLINICAL DECISION SUPPORT TOOL IN PREDICTION OF BIO-NAIVE CROHN'S DISEASE PATIENTS OUTCOMES TREATED WITH ADALIMUMAB OR USTEKINUMAB
UTILITY OF VEDOLIZUMAB CLINICAL DECISION SUPPORT TOOL IN PREDICTION OF BIO-NAIVE CROHN'S DISEASE PATIENTS OUTCOMES TREATED WITH ADALIMUMAB OR USTEKINUMAB

Dominik Kralj  et al.

LONG-TERM TREATMENT PERSISTENCE OF ADALIMUMAB AND USTEKINUMAB IN BIO-NAÏVE PATIENTS WITH CROHN’S DISEASE: A RETROSPECTIVE DATABASE STUDY
LONG-TERM TREATMENT PERSISTENCE OF ADALIMUMAB AND USTEKINUMAB IN BIO-NAÏVE PATIENTS WITH CROHN’S DISEASE: A RETROSPECTIVE DATABASE STUDY

Dominik Kralj  et al.

ARTIFICIAL INTELLIGENCE IN HISTOPATHOLOGICAL DIAGNOSIS OF IBD – A PILOT STUDY
ARTIFICIAL INTELLIGENCE IN HISTOPATHOLOGICAL DIAGNOSIS OF IBD – A PILOT STUDY

Dominik Kralj  et al.

ELEVATED FECAL CALPROTECTIN IS GOOD INDICATOR OF PERSISTENT HISTOLOGICAL ACTIVITY DESPITE ENDOSCOPIC REMISSION IN UC PATIENTS TREATED WITH BIOLOGICS
ELEVATED FECAL CALPROTECTIN IS GOOD INDICATOR OF PERSISTENT HISTOLOGICAL ACTIVITY DESPITE ENDOSCOPIC REMISSION IN UC PATIENTS TREATED WITH BIOLOGICS

Dominik Kralj  et al.

BIO-NAIVE CROHN'S DISEASE PATIENTS WITH LONG-STANDING DISEASE BENEFIT FROM USTEKINUMAB TREATMENT: REAL WORLD EXPERIENCE
BIO-NAIVE CROHN'S DISEASE PATIENTS WITH LONG-STANDING DISEASE BENEFIT FROM USTEKINUMAB TREATMENT: REAL WORLD EXPERIENCE

Dominik Kralj  et al.

Item 1 - 8 / 8
1